Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease
We previously observed that inflammatory bowel disease (IBD) may compromise oral host defense, as assessed by decreased salivary levels of immunoglobulin A (IgA) and myeloperoxidase (MPO). Biologic therapy with inhibitors of cytokines or adhesion molecules is increasingly used for patients with IBD....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/12/1409 |
| _version_ | 1797502936839880704 |
|---|---|
| author | Kacper Nijakowski Rafał Rutkowski Piotr Eder Katarzyna Korybalska Janusz Witowski Anna Surdacka |
| author_facet | Kacper Nijakowski Rafał Rutkowski Piotr Eder Katarzyna Korybalska Janusz Witowski Anna Surdacka |
| author_sort | Kacper Nijakowski |
| collection | DOAJ |
| description | We previously observed that inflammatory bowel disease (IBD) may compromise oral host defense, as assessed by decreased salivary levels of immunoglobulin A (IgA) and myeloperoxidase (MPO). Biologic therapy with inhibitors of cytokines or adhesion molecules is increasingly used for patients with IBD. Little is known, however, about how this treatment modality affects the release and properties of saliva. Here, we aimed to determine how biologic therapy in patients who had not responded to previous standard treatment with conventional drugs affected the salivary concentration of IgA and MPO. To this end, unstimulated whole mixed saliva was collected before treatment or after 10–12 weeks of therapy from 27 patients with Crohn’s disease (CD) and 24 patients with ulcerative colitis (UC). After the induction phase of therapy with biologics, salivary levels of IgA and MPO increased significantly in UC, but not in CD patients. These increases were approximately 8-fold and 6-fold, for IgA and MPO, respectively. Moreover, these effects occurred in UC patients who responded successfully to therapy, but not in those who failed to improve. Furthermore, the relative increases in salivary IgA and MPO correlated with the relative decrease in UC severity, as assessed by the Mayo scale. These data indicate that the successful therapy with biologics in UC patients results also in improved oral host defense. However, it remains to be determined why such an effect does not occur during therapy for CD. |
| first_indexed | 2024-03-10T03:43:17Z |
| format | Article |
| id | doaj.art-ba62c47fcaac40959753354ecd855688 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T03:43:17Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-ba62c47fcaac40959753354ecd8556882023-11-23T09:15:04ZengMDPI AGLife2075-17292021-12-011112140910.3390/life11121409Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel DiseaseKacper Nijakowski0Rafał Rutkowski1Piotr Eder2Katarzyna Korybalska3Janusz Witowski4Anna Surdacka5Department of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, 60-812 Poznan, PolandDepartment of Pathophysiology, Poznan University of Medical Sciences, 60-806 Poznan, PolandDepartment of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznan, PolandDepartment of Pathophysiology, Poznan University of Medical Sciences, 60-806 Poznan, PolandDepartment of Pathophysiology, Poznan University of Medical Sciences, 60-806 Poznan, PolandDepartment of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, 60-812 Poznan, PolandWe previously observed that inflammatory bowel disease (IBD) may compromise oral host defense, as assessed by decreased salivary levels of immunoglobulin A (IgA) and myeloperoxidase (MPO). Biologic therapy with inhibitors of cytokines or adhesion molecules is increasingly used for patients with IBD. Little is known, however, about how this treatment modality affects the release and properties of saliva. Here, we aimed to determine how biologic therapy in patients who had not responded to previous standard treatment with conventional drugs affected the salivary concentration of IgA and MPO. To this end, unstimulated whole mixed saliva was collected before treatment or after 10–12 weeks of therapy from 27 patients with Crohn’s disease (CD) and 24 patients with ulcerative colitis (UC). After the induction phase of therapy with biologics, salivary levels of IgA and MPO increased significantly in UC, but not in CD patients. These increases were approximately 8-fold and 6-fold, for IgA and MPO, respectively. Moreover, these effects occurred in UC patients who responded successfully to therapy, but not in those who failed to improve. Furthermore, the relative increases in salivary IgA and MPO correlated with the relative decrease in UC severity, as assessed by the Mayo scale. These data indicate that the successful therapy with biologics in UC patients results also in improved oral host defense. However, it remains to be determined why such an effect does not occur during therapy for CD.https://www.mdpi.com/2075-1729/11/12/1409inflammatory bowel diseasebiologic therapysalivabiomarkersmyeloperoxidaseimmunoglobulin A |
| spellingShingle | Kacper Nijakowski Rafał Rutkowski Piotr Eder Katarzyna Korybalska Janusz Witowski Anna Surdacka Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease Life inflammatory bowel disease biologic therapy saliva biomarkers myeloperoxidase immunoglobulin A |
| title | Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease |
| title_full | Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease |
| title_fullStr | Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease |
| title_full_unstemmed | Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease |
| title_short | Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease |
| title_sort | changes in salivary parameters of oral immunity after biologic therapy for inflammatory bowel disease |
| topic | inflammatory bowel disease biologic therapy saliva biomarkers myeloperoxidase immunoglobulin A |
| url | https://www.mdpi.com/2075-1729/11/12/1409 |
| work_keys_str_mv | AT kacpernijakowski changesinsalivaryparametersoforalimmunityafterbiologictherapyforinflammatoryboweldisease AT rafałrutkowski changesinsalivaryparametersoforalimmunityafterbiologictherapyforinflammatoryboweldisease AT piotreder changesinsalivaryparametersoforalimmunityafterbiologictherapyforinflammatoryboweldisease AT katarzynakorybalska changesinsalivaryparametersoforalimmunityafterbiologictherapyforinflammatoryboweldisease AT januszwitowski changesinsalivaryparametersoforalimmunityafterbiologictherapyforinflammatoryboweldisease AT annasurdacka changesinsalivaryparametersoforalimmunityafterbiologictherapyforinflammatoryboweldisease |